Connor, Clark & Lunn Investment Management (CC&L)
PDSB icon

Connor, Clark & Lunn Investment Management (CC&L)’s PDS Biotechnology PDSB Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-27,807
Closed -$140K – 1495
2023
Q2 		$140K Sell
27,807
-19,715
-41% -$129K ﹤0.01% 1230
2023
Q1 		$292K Buy
47,522
+19,795
+71% +$162K ﹤0.01% 1012
2022
Q4 		$366K Buy
+27,727
New +$196K ﹤0.01% 945

Other funds holding PDSB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PDSB Position: Q3 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of PDS Biotechnology (PDSB) in Q3 2023, closing a stake of 27,807 shares — an estimated $140K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PDSB in Q4 2022 and held it in 3 quarters. The position peaked at $366K in Q4 2022. 78 funds tracked by Wall St. Rank hold PDSB as of Q3 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining PDS Biotechnology position as of Q3 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 27,807 PDS Biotechnology shares in Q3 2023, an estimated $140K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PDS Biotechnology in Q4 2022 and held it in 3 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s PDS Biotechnology position peaked at $366K in Q4 2022.
  • 78 funds tracked by Wall St. Rank held PDS Biotechnology as of Q3 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q3 2023, filed 13 Nov 2023.